


## Westminster Health Forum policy conference:

### Next steps for medicine regulation in the UK

Timing: Morning, Thursday, 2<sup>nd</sup> October 2025

\*\*\*Taking place online\*\*\*



WESTMINSTER  
HEALTH FORUM

Draft agenda subject to change

- 8.30 Registration
- 9.00 **Chair's opening remarks**  
Senior Parliamentarian
- 9.05 **Supporting the safe regulation of new personalised therapies and streamlining patient access pathways**  
**Professor Sir Munir Pirmohamed**, David Weatherall Chair of Medicine and Honorary Consultant Physician, University of Liverpool; Director, Centre for Drug Safety Science and Wolfson Centre for Personalised Medicine; and Chair, Highly Personalised Medicines Expert Working Group  
Questions and comments from the floor
- 9.30 **The way forward for personalised therapies - regulation, patient access and system readiness**  
*preparing the NHS for deployment of new personalised technologies | diagnostics and pathways for patient access | increasing access to clinical trials | the future of individualised mRNA cancer immunotherapies | next steps for cell and gene therapies | pharmacovigilance and priorities for personalised medicine | developing guidance on regulatory models for whole genome sequencing and other early intervention technologies | regulatory alignment in prescribing settings | opportunities for international regulatory alignment | decentralised manufacturing*  
Senior representative, industry  
Senior representative, NHS  
Senior representative, patient group  
Senior representative, research  
Senior commentator  
Questions and comments from the floor
- 10.20 **Priorities for collaboration in improving patient access to innovation**  
Senior representative, guidelines  
Questions and comments from the floor
- 10.45 **Chair's closing remarks**  
Senior Parliamentarian
- 10.50 Break
- 11.00 **Chair's opening remarks**  
Senior Parliamentarian
- 11.05 **Making the UK an attractive place for medicine research and development**  
**Dan O'Connor**, Director, Regulatory and Early Access Policy, Association of the British Pharmaceutical Industry
- 11.15 **Clinical trial regulation reform - strategies for improving inclusivity and public trust**  
Senior representative, research
- 11.25 Questions and comments from the floor
- 11.40 **Streamlining access to innovation - next steps for emerging technologies, priorities for regulation following the Life Sciences Sector Plan, and plans for innovation and prevention in the 10-Year Health Plan**  
*updated Innovative Licensing and Access Pathway and developer access to early engagement | post-market surveillance, notification requirements and corrective action | role of the Regulatory Innovation Office | upcoming DHSC investment and priorities from the 2025 Spending Review | implementation of new medical device regulations | ensuring patient safety while progressing innovation | adapting regulatory frameworks as technologies become more complex | developing evidence for new AI technologies | use of environmental data in regulatory and procurement decisions | next steps for Centres of Excellence in Regulatory Science and Innovation | priorities for international alignment | role of regulation in supporting digital transformation and promoting preventative strategies*  
Senior representative, innovation  
Senior representative, industry  
Senior representative, AI  
Senior representative, legal  
Senior academic  
Questions and comments from the floor
- 12.30 **The future of medicine regulation in the UK**  
**Julian Beach**, Interim Executive Director, Healthcare Quality and Access, Medicines and Healthcare products Regulatory Agency  
Questions and comments from the floor
- 12.55 **Chair's and Westminster Health Forum closing remarks**  
Senior Parliamentarian  
**Jessica Lear**, Westminster Health Forum